This bill requires the Food and Drug Administration to solicit public comment on factors that should be taken into account when considering proposed modifications to approved risk evaluation and mitigation strategies for drugs. The Government Accountability Office must report on the number of proposed modifications that have been granted and the related effects on patient access or provider administration with respect to such drugs.
Received in the Senate.
Introduced in House
Introduced in House
Referred to the House Committee on Energy and Commerce.
checking server…
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line